Response of Babesiosis to Pentamidine Therapy
- PATRICK B. FRANCIOLI, M.D.;
- JAN S. KEITHLY, Ph.D.;
- THOMAS C. JONES, M.D.;
- ROBERT D. BRANDSTETTER, M.D.; and
- DAVID J. WOLF, M.D.
Abstract
Three nonsplenectomized patients were infected with Babesia microti. One had fever, abdominal pain suggesting gallbladder disease, and evidence of disseminated intravascular coagulation; another was considered to have lymphoma, partly because two smears for Babesia before admission were negative. All three patients were treated with pentamidine isethionate and improved clinically. Parasites were no longer seen on smears after 5 days of therapy, but Babesia could still be recovered by hamster inoculation 5 weeks after therapy in one of the patients tested, underscoring the need for this test to properly evaluate eradication of the organism. In one patient, pentamidine was stopped after 7 days because of increased creatinine concentration, and this amount of drug appeared adequate to control the parasitemia. Pain at drug injection sites was a major side effect in all three patients. Pentamidine appears to be useful in controlling clinical manifestations of babesiosis and decreasing parasitemia, but it does not eradicate the organism.
Article and Author Information
-
▸From the Infectious Diseases Division, International Medicine Division, and Hematology-Oncology Division, Department of Medicine, The New York Hospital-Cornell University Medical Center; New York, New York.
-
Grant support: in part by the National Institutes of Health through specialized Center for Thrombosis grant HL 18828 and by the Arnold R. Krakower Foundation. Dr. Francioli was supported by a fellowship from the Centre Hospitalier Universitaire Vaudois, Switzerland, and by the Franz Joseph Foundation.
-
▸Requests for reprints should be addressed to Thomas C. Jones, M.D.; Cornell Medical College, 1300 York Avenue; New York, NY 10021.
- © 1981 American College of Physicians
Most Read